Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

MLA

Daver, Naval, et al. “Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia.” Blood, vol. 142, no. 1, Number 1 Supplement 1, Nov. 2023, p. 2906. EBSCOhost, https://doi.org/10.1182/blood-2023-173413.

APA

Daver, N., Montesinos, P., Altman, J. K., Wang, E. S., Martinelli, G., Roboz, G. J., Begna, K., Vyas, P., Lunghi, M., Platzbecker, U., Burke, P. W., Walter, R. B., Advani, A. S., Garciaz, S., Gastaud, L., Sallman, D. A., Pemmaraju, N., Torres, L., Abaza, Y., … Sweet, K. (2023). Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 142(1, Number 1 Supplement 1), 2906. https://doi.org/10.1182/blood-2023-173413

Chicago

Daver, Naval, Pau Montesinos, Jessica K. Altman, Eunice S. Wang, Giovanni Martinelli, Gail J. Roboz, Kebede Begna, et al. 2023. “Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia.” Blood 142 (1, Number 1 Supplement 1): 2906. doi:10.1182/blood-2023-173413.